Doctor-prescribed GLP-1 weight loss. Delivered to your door.
GLP-1 drugs like Ozempic work. Clinically proven 15–20% weight loss. But in India, the system to deliver them safely doesn't exist.
Branded versions cost ₹8,800–16,000/month — unaffordable for most. Generic semaglutide just launched (patent expired March 20, 2026) and prices dropped to ₹1,300–2,200/month. But DCGI mandates specialist-only prescriptions. Most people don't have access to an endocrinologist. Pharmacists are selling without prescriptions. It's dangerous, and the regulatory crackdown is underway.
There is no dedicated, compliant, convenient platform connecting patients to specialists and affordable generics.
1 in 3 Indian adults is overweight. 101 million are diabetic. By 2030, 404 million Indians will have a high BMI. The Economic Survey 2026 flagged obesity as a major public health threat. It's not just a health crisis — it's a productivity crisis.
Zelta is a doctor-led, AI-powered telehealth platform for GLP-1 weight loss treatment in India. We are a routing layer — not a pharmacy, not a clinic, not a drug company.
Patient takes a 2-minute online health assessment. Books a video consultation with a verified endocrinologist for ₹499. Doctor prescribes generic semaglutide if eligible — real prescription, real registration number. Medication delivered to door via cold-chain in 3–5 days, free shipping. Ongoing support with monthly follow-ups, dosage adjustments, and AI-powered WhatsApp reminders.
All-inclusive: ₹3,999/month. That's 50–65% cheaper than branded Ozempic, with the convenience of never leaving home and the safety of specialist supervision.
Compliant. Specialist-only prescriptions. Schedule H adherence. DCGI-aligned. When the crackdown intensifies, we're the last one standing.
Affordable. Generic semaglutide at 50–70% below branded Ozempic. All-inclusive pricing — no hidden costs.
Convenient. Video consult from home. Medication at your door. WhatsApp support between visits.
AI-first. Website, ads, customer support, content — all AI-powered. Two-person ops energy, billion-rupee scale.
India's GLP-1 market today sits at ₹1,000–1,200 crore. Projected to reach ₹4,500–5,000 crore by 2030 — a 5x jump (CARE Ratings). Nomura pegs the addressable semaglutide opportunity at ₹12,000 crore ($1.4 billion). Current penetration is near zero. GLP-1 drug sales grew 115% in 2025 — before generics even launched.
10+ manufacturers are now producing generic semaglutide: Dr. Reddy's, Zydus, Sun Pharma, Glenmark, Alkem, Lupin, and more.
The demand is real. The supply is here. The platform to connect them doesn't exist. Until now.
Zelta is a routing layer. We don't stock drugs, employ doctors full-time, or run pharmacies.
| Partner | Role |
|---|---|
| Specialist doctors (panel) | Video consultations + prescriptions |
| Licensed pharmacy partner | Fulfillment + cold-chain shipping |
| AI stack | Website, ads, customer service, ops |
| Zelta | Customer acquisition, brand, platform |
Revenue = patient subscription (₹3,999–4,999/month) minus doctor fee (~₹400–800) minus drug cost (~₹1,300–2,200) minus delivery (~₹100–200). Gross margin: 40–55%.
Phase 1 — GLP-1 Weight Loss (Now). Build the most trusted GLP-1 telehealth platform in India. Specialist-led. DCGI-compliant. Affordable. Delivered to your door. Target: 15,000 active patients in Year 1.
Phase 2 — Multi-Vertical (Month 6+). Same machine, new categories. Erectile dysfunction, hair loss, diabetes management, PCOS treatment, Rx skincare. Each vertical uses the same infrastructure: assessment → specialist consult → prescription → delivery → support.
Phase 3 — India's Health Layer. Become the default platform Indians use for prescription health treatments delivered to their home. Not a pharmacy. Not a hospital. The layer in between — where AI handles operations and specialists handle medicine.
The semaglutide patent expired 2 weeks ago. 10+ Indian pharma companies launched generics. Prices crashing. Demand is exploding. DCGI is cracking down on unauthorized sellers — which clears the field for compliant players. There is no dedicated, AI-first, specialist-led GLP-1 platform in India. Every week we wait, someone else fills the gap.
Operating under Upsurge LLP. A focused team where each person owns a vertical end-to-end.
Sowmay — Product & strategy. Website build. Overall direction.
Nikhil & Ankit — Payments, infrastructure & compliance. Domains, Razorpay, Meta Business Suite, all account setups.
Ravi & Naksh — Doctor network & medical ops. Recruiting endocrinologists, pharmacy partnership, prescription flow, medical compliance.
Dilisha & Misba — Logistics & delivery. Cold-chain shipping (2–8°C), delivery partner management, dispatch coordination across 6 metros.
Kuber — Ads & growth. Campaign execution across Meta, Google, YouTube, X. Budget allocation, performance tracking.
Aisurya — Content & social. All social handles, ad creatives, content strategy.
Lauki — Technology & AI ops. Platform automation, AI-powered customer service, operational intelligence.
"A one-person business worth $1 billion would have been unimaginable without A.I., and now it will happen."
— Sam Altman, CEO of OpenAI
It already happened in the US. Now it's India's turn.